Vaccine for Glioblastoma Multiforme is under clinical development by OX2 Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Vaccine for Glioblastoma Multiforme’s likelihood of approval (LoA) and phase transition for Recurrent Glioblastoma Multiforme (GBM) took place on 01 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Vaccine for Glioblastoma Multiforme Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Vaccine for Glioblastoma Multiforme overview

BTIC lysate-based vaccine is under investigation for the treatment of recurrent glioblastoma multiforme (GBM). The vaccine candidate is administered intradermally.

OX2 Therapeutics overview

OX2 Therapeutics, Inc., is a healthcare therapeutics company that focuses on treating brain tumors. The company is headquartered in United States.

Quick View Vaccine for Glioblastoma Multiforme LOA Data

Report Segments
  • Innovator
Drug Name
  • Vaccine for Glioblastoma Multiforme
Administration Pathway
  • Intradermal
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase I

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.